Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AGOCS +0.19%22 3-Year Share Buyback Ratio is -21.00 as of Jun. 2026. GuruFocus rates OCS with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,190 Biotechnology companies, Oculis Holding AG ranks worse than 64.37% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Oculis Holding AG's current 3-Year Share Buyback Ratio was -21.00%.
The historical rank and industry rank for Oculis Holding AG's 3-Year Share Buyback Ratio or its related term are showing as below:
OCS'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -21 Med: -10.1 Max: -3.8
Current: -21
During the past 6 years, Oculis Holding AG's highest 3-Year Share Buyback Ratio was -3.80%. The lowest was -21.00%. And the median was -10.10%.
OCS's 3-Year Share Buyback Ratio is ranked worse than 64.37% of 1190
companies
in the Biotechnology industry
Industry Median: -11.75
vs OCS: -21.00
Oculis Holding AG (NAS:OCS) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Oculis Holding AG 3-Year Share Buyback Ratio Related Terms
OCS vs RIGL, GYRE, SGP: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Oculis Holding AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's 3-Year Share Buyback Ratio falls into.
Oculis Holding AG 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -21.00 mean?
Oculis Holding AG (OCS) has a 3-Year Share Buyback Ratio of -21.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #766 out of 1190 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Oculis Holding AG's 3-Year Share Buyback Ratio too high?
Oculis Holding AG's current 3-Year Share Buyback Ratio is -21.00. Based on the distribution chart, Oculis Holding AG ranks #766 out of 1190 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oculis Holding AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's 3-Year Share Buyback Ratio compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #766 out of 1190 companies for 3-Year Share Buyback Ratio. This places Oculis Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Oculis Holding AG and its competitors. Oculis Holding AG's current 3-Year Share Buyback Ratio is -21.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OCS) has a current 3-Year Share Buyback Ratio of -21.00. The current 3-Year Share Buyback Ratio is -21.00. Oculis Holding AG's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Oculis Holding AG (OCS), the current 3-Year Share Buyback Ratio is -21.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
22GF Score
Get the complete analysis for OCS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCS has been successfully added to your 
